Volume 6, Issue 8

Weight Gain and Hormone Therapy

In this issue:

Do antivirals increase weight gain? Does PrEP reduce the effect of gender-affirming hormone therapy in transgender women? 

Join us in the clinic with Dr. Sarah Puryear from the University of California San Francisco as we discuss these important questions. 

Learning objectives:

  • Describe weight gain as a potential risk of treatment with integrase strand inhibitors (INSTI) and tenofovir alafenamide fumarate (TAF). 
  • Discuss drug-drug interactions as a potential risk of treatment with tenofovir disoproxil fumarate (TDF)-containing PrEP and gender-affirming hormone therapy (GAHT) in transgender patients. 

Author:

Sarah B. Puryear, MD, MPH
Sarah B. Puryear, MD, MPH

Assistant Professor of Medicine 
Division of HIV, ID, and Global Medicine at the University of California, San Francisco 
San Francisco, California

Program Directors:

Ethel D. Weld, MD, PhD

Assistant Professor of Medicine and Pharmacology and Molecular Sciences
Division of Infectious Diseases
Division of Clinical Pharmacology
Johns Hopkins School of Medicine
Baltimore, Maryland
(she/her/hers)

Matthew Spinelli, MD, MAS

Assistant Professor
HIV, ID, and Global Medicine
Zuckerberg San Francisco General Hospital
San Francisco, California
(he/him/his)

Justin Alves, RN, FNP-BC, ACRN, CARN, CNE

Nurse Educator
Boston Medical Center
Boston, MA
(he/him/his)

Length of activity:

0.5 hour Physicians
0.5 contact hour Nurses

Launch date: May 27, 2021
Expiration date: May 26, 2023